Gastric CancerTOREGANCT03568110
Frailty and Postoperative Outcomes After Gastric Cancer Surgery
An observational study of Gastric Cancer and Frail Elderly Syndrome, run by Parc de Salut Mar at 1 site in Spain.
Trial summary
Background. Gastric cancer is an important health care problem even though treatment advances, and it is diagnosed mainly in elderly. Surgery is the main treatment for gastric cancer and is associated with a high rate of postoperative complications and mortality, even higher in older patients. Read more about this study
- Who is it for?
- Ages 70 years and older
- Conditions the study is for
- Gastric Cancer, Frail Elderly Syndrome, Postoperative Complications
- How many people
- 432 participants
- Where
- 1 siteSpain
- Study dates
- 5 Mar 2019to 30 Apr 2023
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 70 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: The possibility to participate to the study will be offered to all the hospitals members of the Spanish EURECCA Esophagogastric Cancer Registry. The hospitals that will participate must sign a commitment. Every patient that fit the eligibility criteria will be part of the study.
Who may be able to join
- ≥ 70 years patients diagnosed with gastric cancer candidates for radical resection
Who cannot join
- metastatic patients
- patients candidates for palliative treatment
- patients without a signed informed consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Impact of Frailty on the Postoperative Outcomes of Gastric Cancer Surgery
Background. Gastric cancer is an important health care problem even though treatment advances, and it is diagnosed mainly in elderly. Surgery is the main treatment for gastric cancer and is associated with a high rate of postoperative complications and mortality, even higher in older patients. Chronological age seems not to be the main factor influencing the worse outcome of older patients, comorbidities and frailty have also been taken into account recently.
Methods. Participation in the study will be offered to all centers that are currently part of the Spanish EURECCA (EUropean REgistry of Cancer CAre) Esophagogastric Cancer Registry. The impact of the frailty on different outcome variables will be evaluated. The main outcome variable will be 90-day mortality after the intervention. Health-Related Quality of Life (HRQoL) will also be evaluated.
Objective. The objective of the study is to value the impact of frailty on gastric cancer surgery outcomes therein the Spanish EURECCA Esophagogastric Cancer Registry.
Read the detailed description
Introduction
Gastric cancer is the fifth most frequent cancer and the third cause of death due to cancer. The increase in life expectancy cause it to be diagnosed more and more in elderly people, with an average age at diagnosis of 68 years in the West.
Surgery is the main treatment for gastric cancer and is associated with a high rate of postoperative complications and mortality, which is even higher in elderly patients (data from the ACS-NSQIP between 2007 and 2013: 30-day severe morbidity from 16.3% in 80 years and 30-day mortality from 1.2% in 80 years).
Generally, advanced chronological age is considered a negative prognostic factor for complications and hospital stay in major surgery. Age per se, however, seems to be responsible only in part for the increased risk of postoperative complications.
Greater risks seem to be associated with other factors such as comorbidities, so, in the preoperative evaluation, variables such as the Charlson comorbidity index have been introduced. Another variable that has emerged recently for the estimation of perioperative risk is frailty, which is defined as "a medical syndrome with multiple causes and contributors that is characterized by a decrease in strength, endurance and physiological capacity, which increases the risk of the vulnerability of the individual and/or death". Surgery is a major stress factor that can disrupt physiological homeostasis; therefore, frailty has a clinical significance when considering surgery in elderly patients.
There are two main ways to measure frailty: one by clinical definitions of a fragile phenotype and another by frailty indexes that assess the accumulated deficits in multiple domains. Measures to assess frailty are numerous and this is a limitation when standardizing and comparing studies; among the most used there are the Fried criteria, the frailty index of the Canadian Study of Health and Aging (CSHA-FI) and the modified frailty index of Velanovich (mFI: modified Frailty Index).
Other indices widely used in the clinic are the Geriatric 8 (G8), which is recommended above all in elderly patients with cancer and the Groningen index (GFI: Groningen Frailty Indicator). The prevalence of frailty in elderly patients (65 years or older) is highly variable, probably due to the diversity in the definitions of frailty (4.0-59.1% in community residences, 10.4-56.0% in patients who are candidates for elective surgery) (18, 19, 20). The prevalence of frailty increases in females and with age (being 15.7% in patients aged 80-84 years and 26.1% in patients older than 85 years).
Frailty appears in several studies as a more important indicator than chronological age with respect to postoperative results. There are evidences that relate frailty, evaluated with different indices, with the increase of postoperative complications, hospital stay, need of discharge to convalescence centers, health costs, short and long term mortality, after major surgery.
Therefore, it is important to identify fragile patients to implement prevention programs through global geriatric assessments (CGA Comprehensive Geriatric Assessment). Just by having more clinical attention for more fragile patients after major surgery there can be better results of short and long-term postoperative mortality. Likewise, as demonstrated in randomized clinical studies, prehabilitation and global geriatric assessment programs improve the results in terms of postoperative complications and hospital stay.
The CGA is an established method to evaluate and optimize the physical state, the psychological, functional and social problems in elderly patients in order to improve the results of the treatments. It implies an interdisciplinary evaluation of multiple domains, followed by planning for analysis, treatment, rehabilitation and long-term follow-up.
This allows, in the first place, to intervene before an operation, to increase the physiological reserve of a patient, especially with exercise and nutrition. In addition, the therapeutic decision can be guided by adapting the surgical recommendations to the physiological capacity of the patient; second, the knowledge of the increased risk of complications and the possible need for transfer to institutions (especially in patients who live alone) prepares patients and their families for postoperative evolution.
The majority of studies published in the literature on the relationship between frailty and postoperative results are retrospective studies, which evaluate populations of patients undergoing major surgery and who, in general, analyze short-term results (30-day mortality). None of these takes into account the impact of surgery on the quality of life of this group of patients. Among all these studies there is very little information about the influence of frailty in gastric cancer surgery. There is only one retrospective study that focuses only on gastric cancer surgery, using the Groningen index and revealing an increase in in-hospital mortality and serious complications (Clavien-Dindo complications score ≥ 3) in fragile patients.
Objective
The aim of the present study is to assess the impact of frailty on the results of gastric cancer surgery (long-term postoperative morbidity and mortality, hospital stay, readmissions, need of transfer to institution of medium or long stay and quality of life).
Methods
This is a prospective and multicenter cohort study, within the Spanish EURECCA Esophagogastric Cancer Project, to investigate the impact of frailty on the postoperative results of surgery for gastric cancer in elderly patients.
Participation in the study will be offered to all centers that are currently part of the Spanish EURECCA Esophagogastric Cancer Registry. Those hospitals that show their desire to participate must sign the Letter of Commitment.
The impact of the frailty on different outcome variables will be evaluated. The main outcome variable will be 90-day mortality after the intervention. Other secondary outcome variables will also be evaluated: incidence of serious complications (Clavien-Dindo complications score ≥ 3), Complication Comprehensive Index (CCI) score, hospital stay, incidence of death in patients suffering from a complication (failure-to-rescue), hospital readmission within the first 30 days after the discharge, destination of the patient after discharge from hospital [home, social health centers, or geriatric residence], mortality at 12 months after the intervention, quality of life before the intervention and at 12 months.
For the assessment of frailty (frailty screening), two questionnaires will be used:
- Questionnaire G8: This is a questionnaire with 8 questions, easy to use, with a total score that varies from 0 to 17 points. Previous studies suggest the score ≤ 14 as a cut-off point to identify the fragile patient, with a sensitivity of 92% and specificity of 52%.
- Modified frailty index: This index was described by Velanovich et al., based on a previously validated simplification of the frailty index CSHAFI (Canadian Study of Health and Aging Frailty Index), which was specifically designed to analyze data included in the National Surgical Quality Improvement Program of the American College of Surgeons (ACSNSQIP). It consists of 11 questions with 1 point assigned to each of them on the functional, endocrine, respiratory, cardiovascular and neurological status of the patient. It allows to divide the patients into 4 groups: without frailty (FI = 0), slightly fragile (FI = 1), moderately fragile (FI = 2) and severely fragile (FI ≥ 3).
Postoperative complications will be classified according to the recommendations proposed by the European Chapter of the International Gastric Cancer Association (EGCA) (unpublished data), its severity through the classification of Clavien-Dindo and the CCI. In particular, the CCI will be calculated using the free application that can be found on the website: www.assessurgery.com/calculator_single/.
Health-Related Quality of Life (HRQoL) will be evaluated with the validated Quality of Life questionnaires of the European Organization for Research and Treatment of Cancer (EORTC-QLQ), QLQ-C30 (30 items Core Quality of Life Questionnaire, version 3.0) and with the specific module for gastric cancer QLQ-STO22 (22 items Stomach Quality of Life Questionnaire). The permission for its use by the EORTC is available.
- The EORTC-QLQ-C30 is a questionnaire that reflects the multidimensionality of HRQoL in patients with cancer. It is composed of 30 questions distributed in five functional scales (physical, role, cognitive, emotional and social), three scales of symptoms (fatigue, pain and nausea and vomiting), a global health scale and a series of additional questions to evaluate symptoms commonly referred by patients diagnosed with cancer (dyspnea, loss of appetite, insomnia, constipation and diarrhea) and the perceived financial impact.
- The EORTC-QLQ-STO22 questionnaire contains 22 structured items in five domains (dysphagia, food restrictions, pain, reflux and anxiety) and four specific items (dry mouth, alteration of taste perception, body image and hair loss) related to the symptoms of the disease.
The calculation of the sample size is based on the primary objective of comparing fragile versus non-fragile patients with respect to postoperative mortality at 90 days after the intervention. Based on mortality data previously published in a retrospective study by Mosquera et al., it is estimated that mortality for the group of non-frail patients is 0.6% and for the group with frailty 4.3%. From the data of the literature, a prevalence of 23% of frailty is calculated in the population of patients with gastric cancer and age ≥ 70 years undergoing gastrectomy.
For a power of 80% and a level of significance of 95% in a unilateral analysis, it is estimated that 276 non-fragile patients and 92 fragile patients would be needed to detect as statistically significant the difference between the proportion of patients who die between both groups.
The characteristics of fragile and non-fragile patient groups will be compared through frequency tables. The Chi-square test will be used to compare the differences between the categorical variables and the ANOVA test for the continuous variables. Different analyzes are proposed according to the study variables that are to be analyzed. For dichotomous type response variables (90- day mortality, 12-month mortality, incidence of serious complications, incidence of in-hospital death in patients with complications, and hospital readmission at 30 days after discharge), a multivariate logistic regression will be used to evaluate the risk (odds ratio) of these variables. For continuous response variables (ICC score) at 30 days after the intervention, and number of days of hospital stay), linear regression models will be used. For the variable categorical response of the patient after hospital discharge, an ordinal logistic regression model will be done. All regression models will be adjusted for age, sex, body mass index (BMI), type of gastrectomy, center volume, neoadjuvant treatment and degree of frailty. Regarding HRQoL analysis, the mean scores and 95% confidence intervals for the different domains of preoperative HRQoL and one year after surgery will be calculated. Changes of more than 10 points on a scale from 0 to 100 will be considered clinically relevant as previously suggested in other publications.
- Medical subject headings
- Stomach Neoplasms, Postoperative Complications
What is being measured
The primary outcome is the main question the study is designed to answer.
90-day mortality
Mortality at 90 days after surgery
Measured: 90 days after surgery
Secondary outcomes (11)
Severe complications
Postoperative complications Clavien-Dindo score ≥ III
Clavien-Dindo score:
Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions
Grade II Requiring pharmacological treatment with drugs other than such allowed for grade I complications
Grade III Requiring surgical, endoscopic or radiological intervention
- IIIa Intervention not under general anesthesia
- IIIb Intervention under general anesthesia
Grade IV Life-threatening complication requiring Intensive Care Unit-management
- IVa single organ dysfunction (including dialysis)
- IVb multiorgandysfunction Grade V Death of a patient
Higher values represent a worse outcome.
Measured: 30 days after surgery
Complication Comprehensive Index
Complication Comprehensive Index from www.assessurgery.com/calculator_single/
The CCI® calculator is an online tool to support the assessment of patients' overall morbidity. The Comprehensive Complication Index (CCI®) is based on the complication grading by Clavien-Dindo Classification and implements every occurred complication after an intervention. The overall morbidity is reflected on a scale from 0 (no complication) to 100 (death). CCI® =√ (wC1 + wC2 ...+ wCx ) /2.
Higher values represent a worse outcome.
Measured: 30 days after surgery
Failure to rescue
Postoperative death after a treatable complication
Measured: 30 days after surgery
Hospital stay
Number of days of hospital stay
Measured: 30 days after surgery
Patient discharge facility
Facility where the patient goes after the hospital stay
Measured: 30 days after surgery
Readmission
Readmission within 30 days after discharge
Measured: 30 days after discharge
12-month mortality
Mortality at 12 months after surgery
Measured: 12 months after surgery
Health-related Quality of life before the intervention (EORTC-QLQ-C30)
Quality of life before the intervention evaluated with the EORTC (European Organization for Research and Treatment of Cancer) QLQ-C30 questionnaire:
- The EORTC-QLQ-C30 (30 items Core Quality of Life Questionnaire) includes five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level (a high/healthy level of functioning in functional scales, a high Quality of Life in Quality of Life scales, a high level of symptomatology/problems in symptom scales).
Measured: 2 weeks before surgery
Health-related Quality of life before the intervention (EORTC-QLQ-STO22)
Quality of life before the intervention evaluated with the EORTC (European Organization for Research and Treatment of Cancer) QLQ-STO22 questionnaire:
- The QLQ-STO22 (22 items Stomach Quality of Life Questionnaire) consists of five multi-item symptoms scales and four single symptoms items. All of the scales and single-item measures range in score from 0 to 100. Higher scores represent greater level of symptoms.
Measured: 2 weeks before surgery
Health-related Quality of life at 12 months (EORTC-QLQ-C30)
Quality of life before the intervention evaluated with the EORTC (European Organization for Research and Treatment of Cancer) QLQ-C30 questionnaire:
- The EORTC-QLQ-C30 (30 items Core Quality of Life Questionnaire) includes five functional scales, three symptom scales, a global health status/QoL scale, and six single items. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level (a high/healthy level of functioning in functional scales, a high Quality of Life in Quality of Life scales, a high level of symptomatology/problems in symptom scales).
Measured: 12 months after surgery
Health-related Quality of life at 12 months (EORTC-QLQ-STO22)
Quality of life before the intervention evaluated with the EORTC (European Organization for Research and Treatment of Cancer) QLQ-STO22 questionnaire:
- The QLQ-STO22 (22 items Stomach Quality of Life Questionnaire) consists of five multi-item symptoms scales and four single symptoms items. All of the scales and single-item measures range in score from 0 to 100. Higher scores represent greater level of symptoms.
Measured: 12 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2018
- Study start5 Mar 2019
- Primary completion30 Apr 2023
- Study completion30 Apr 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (37)Papers the sponsor has linked to this study.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 432 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Parc de Salut Mar
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Manuel Ramón Pera Román, Parc de Salut Mar
- Investigators
- Manuel Pera, Principal investigator, Parc de Salut Mar
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03568110
- Sponsor's protocol ID
- 1
- Acronym
- TOREGA
- Status last verified
- Nov 2023
- First submitted
- 9 May 2018
- Last updated
- 28 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Hamilton TD, Mahar AL, Haas B, Beyfuss K, Law CHL, Karanicolas PJ, Coburn NG, Hallet J. The impact of advanced age on short-term outcomes following gastric cancer resection: an ACS-NSQIP analysis. Gastric Cancer. 2018 Jul;21(4):710-719. doi: 10.1007/s10120-017-0786-6. Epub 2017 Dec 11.
PubMed 29230588Polanczyk CA, Marcantonio E, Goldman L, Rohde LE, Orav J, Mangione CM, Lee TH. Impact of age on perioperative complications and length of stay in patients undergoing noncardiac surgery. Ann Intern Med. 2001 Apr 17;134(8):637-43. doi: 10.7326/0003-4819-134-8-200104170-00008.
PubMed 11304103Kim SW, Han HS, Jung HW, Kim KI, Hwang DW, Kang SB, Kim CH. Multidimensional frailty score for the prediction of postoperative mortality risk. JAMA Surg. 2014 Jul;149(7):633-40. doi: 10.1001/jamasurg.2014.241.
PubMed 24804971Tegels JJ, Stoot JH. Way forward: Geriatric frailty assessment as risk predictor in gastric cancer surgery. World J Gastrointest Surg. 2015 Oct 27;7(10):223-5. doi: 10.4240/wjgs.v7.i10.223.
PubMed 26523209Partridge JS, Harari D, Dhesi JK. Frailty in the older surgical patient: a review. Age Ageing. 2012 Mar;41(2):142-7. doi: 10.1093/ageing/afr182.
PubMed 22345294Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013 Jun;14(6):392-7. doi: 10.1016/j.jamda.2013.03.022.
PubMed 23764209Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146.
PubMed 11253156Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):722-7. doi: 10.1093/gerona/62.7.722.
PubMed 17634318McIsaac DI, Bryson GL, van Walraven C. Association of Frailty and 1-Year Postoperative Mortality Following Major Elective Noncardiac Surgery: A Population-Based Cohort Study. JAMA Surg. 2016 Jun 1;151(6):538-45. doi: 10.1001/jamasurg.2015.5085.
PubMed 26791334Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95. doi: 10.1503/cmaj.050051.
PubMed 16129869Velanovich V, Antoine H, Swartz A, Peters D, Rubinfeld I. Accumulating deficits model of frailty and postoperative mortality and morbidity: its application to a national database. J Surg Res. 2013 Jul;183(1):104-10. doi: 10.1016/j.jss.2013.01.021. Epub 2013 Feb 1.
PubMed 23415494Bellera CA, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, Soubeyran PL. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012 Aug;23(8):2166-2172. doi: 10.1093/annonc/mdr587. Epub 2012 Jan 16.
PubMed 22250183Smets IH, Kempen GI, Janssen-Heijnen ML, Deckx L, Buntinx FJ, van den Akker M. Four screening instruments for frailty in older patients with and without cancer: a diagnostic study. BMC Geriatr. 2014 Feb 26;14:26. doi: 10.1186/1471-2318-14-26.
PubMed 24571290Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012 Aug;60(8):1487-92. doi: 10.1111/j.1532-5415.2012.04054.x. Epub 2012 Aug 6.
PubMed 22881367Robinson TN, Wu DS, Pointer L, Dunn CL, Cleveland JC Jr, Moss M. Simple frailty score predicts postoperative complications across surgical specialties. Am J Surg. 2013 Oct;206(4):544-50. doi: 10.1016/j.amjsurg.2013.03.012. Epub 2013 Jul 20.
PubMed 23880071
Study at a glance
From the registry record, last updated by the sponsor on 28 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Frailty on the Postoperative Outcomes of Gastric Cancer Surgery
- ClinicalTrials.gov ID
- NCT03568110
- Acronym / sponsor ID
- TOREGA / 1
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 432 participants (actual)
- Lead sponsor
- Parc de Salut MarUniversity, hospital or other
- Study start
- 5 Mar 2019 (actual)
- Primary completion
- 30 Apr 2023 (actual)
- Study completion
- 30 Apr 2023 (actual)
- First posted
- 26 Jun 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background. Gastric cancer is an important health care problem even though treatment advances, and it is diagnosed mainly in elderly. Surgery is the main treatment for gastric cancer and is associated with a high rate of postoperative complications and mortality, even higher in older patients. Chronological age seems not to be the main factor influencing the worse outcome of older patients, comorbidities and frailty have also been taken into account recently.
Methods. Participation in the study will be offered to all centers that are currently part of the Spanish EURECCA (EUropean REgistry of Cancer CAre) Esophagogastric Cancer Registry. The impact of the frailty on different outcome variables will be evaluated. The main outcome variable will be 90-day mortality after the intervention. Health-Related Quality of Life (HRQoL) will also be evaluated.
Objective. The objective of the study is to value the impact of frailty on gastric cancer surgery outcomes therein the Spanish EURECCA Esophagogastric Cancer Registry.
Detailed description
Introduction
Gastric cancer is the fifth most frequent cancer and the third cause of death due to cancer. The increase in life expectancy cause it to be diagnosed more and more in elderly people, with an average age at diagnosis of 68 years in the West.
Surgery is the main treatment for gastric cancer and is associated with a high rate of postoperative complications and mortality, which is even higher in elderly patients (data from the ACS-NSQIP between 2007 and 2013: 30-day severe morbidity from 16.3% in 80 years and 30-day mortality from 1.2% in 80 years).
Generally, advanced chronological age is considered a negative prognostic factor for complications and hospital stay in major surgery. Age per se, however, seems to be responsible only in part for the increased risk of postoperative complications.
Greater risks seem to be associated with other factors such as comorbidities, so, in the preoperative evaluation, variables such as the Charlson comorbidity index have been introduced. Another variable that has emerged recently for the estimation of perioperative risk is frailty, which is defined as "a medical syndrome with multiple causes and contributors that is characterized by a decrease in strength, endurance and physiological capacity, which increases the risk of the vulnerability of the individual and/or death". Surgery is a major stress factor that can disrupt physiological homeostasis; therefore, frailty has a clinical significance when considering surgery in elderly patients.
There are two main ways to measure frailty: one by clinical definitions of a fragile phenotype and another by frailty indexes that assess the accumulated deficits in multiple domains. Measures to assess frailty are numerous and this is a limitation when standardizing and comparing studies; among the most used there are the Fried criteria, the frailty index of the Canadian Study of Health and Aging (CSHA-FI) and the modified frailty index of Velanovich (mFI: modified Frailty Index).
Other indices widely used in the clinic are the Geriatric 8 (G8), which is recommended above all in elderly patients with cancer and the Groningen index (GFI: Groningen Frailty Indicator). The prevalence of frailty in elderly patients (65 years or older) is highly variable, probably due to the diversity in the definitions of frailty (4.0-59.1% in community residences, 10.4-56.0% in patients who are candidates for elective surgery) (18, 19, 20). The prevalence of frailty increases in females and with age (being 15.7% in patients aged 80-84 years and 26.1% in patients older than 85 years).
Frailty appears in several studies as a more important indicator than chronological age with respect to postoperative results. There are evidences that relate frailty, evaluated with different indices, with the increase of postoperative complications, hospital stay, need of discharge to convalescence centers, health costs, short and long term mortality, after major surgery.
Therefore, it is important to identify fragile patients to implement prevention programs through global geriatric assessments (CGA Comprehensive Geriatric Assessment). Just by having more clinical attention for more fragile patients after major surgery there can be better results of short and long-term postoperative mortality. Likewise, as demonstrated in randomized clinical studies, prehabilitation and global geriatric assessment programs improve the results in terms of postoperative complications and hospital stay.
The CGA is an established method to evaluate and optimize the physical state, the psychological, functional and social problems in elderly patients in order to improve the results of the treatments. It implies an interdisciplinary evaluation of multiple domains, followed by planning for analysis, treatment, rehabilitation and long-term follow-up.
This allows, in the first place, to intervene before an operation, to increase the physiological reserve of a patient, especially with exercise and nutrition. In addition, the therapeutic decision can be guided by adapting the surgical recommendations to the physiological capacity of the patient; second, the knowledge of the increased risk of complications and the possible need for transfer to institutions (especially in patients who live alone) prepares patients and their families for postoperative evolution.
The majority of studies published in the literature on the relationship between frailty and postoperative results are retrospective studies, which evaluate populations of patients undergoing major surgery and who, in general, analyze short-term results (30-day mortality). None of these takes into account the impact of surgery on the quality of life of this group of patients. Among all these studies there is very little information about the influence of frailty in gastric cancer surgery. There is only one retrospective study that focuses only on gastric cancer surgery, using the Groningen index and revealing an increase in in-hospital mortality and serious complications (Clavien-Dindo complications score ≥ 3) in fragile patients.
Objective
The aim of the present study is to assess the impact of frailty on the results of gastric cancer surgery (long-term postoperative morbidity and mortality, hospital stay, readmissions, need of transfer to institution of medium or long stay and quality of life).
Methods
This is a prospective and multicenter cohort study, within the Spanish EURECCA Esophagogastric Cancer Project, to investigate the impact of frailty on the postoperative results of surgery for gastric cancer in elderly patients.
Participation in the study will be offered to all centers that are currently part of the Spanish EURECCA Esophagogastric Cancer Registry. Those hospitals that show their desire to participate must sign the Letter of Commitment.
The impact of the frailty on different outcome variables will be evaluated. The main outcome variable will be 90-day mortality after the intervention. Other secondary outcome variables will also be evaluated: incidence of serious complications (Clavien-Dindo complications score ≥ 3), Complication Comprehensive Index (CCI) score, hospital stay, incidence of death in patients suffering from a complication (failure-to-rescue), hospital readmission within the first 30 days after the discharge, destination of the patient after discharge from hospital [home, social health centers, or geriatric residence], mortality at 12 months after the intervention, quality of life before the intervention and at 12 months.
For the assessment of frailty (frailty screening), two questionnaires will be used:
- Questionnaire G8: This is a questionnaire with 8 questions, easy to use, with a total score that varies from 0 to 17 points. Previous studies suggest the score ≤ 14 as a cut-off point to identify the fragile patient, with a sensitivity of 92% and specificity of 52%.
- Modified frailty index: This index was described by Velanovich et al., based on a previously validated simplification of the frailty index CSHAFI (Canadian Study of Health and Aging Frailty Index), which was specifically designed to analyze data included in the National Surgical Quality Improvement Program of the American College of Surgeons (ACSNSQIP). It consists of 11 questions with 1 point assigned to each of them on the functional, endocrine, respiratory, cardiovascular and neurological status of the patient. It allows to divide the patients into 4 groups: without frailty (FI = 0), slightly fragile (FI = 1), moderately fragile (FI = 2) and severely fragile (FI ≥ 3).
Postoperative complications will be classified according to the recommendations proposed by the European Chapter of the International Gastric Cancer Association (EGCA) (unpublished data), its severity through the classification of Clavien-Dindo and the CCI. In particular, the CCI will be calculated using the free application that can be found on the website: www.assessurgery.com/calculator_single/.
Health-Related Quality of Life (HRQoL) will be evaluated with the validated Quality of Life questionnaires of the European Organization for Research and Treatment of Cancer (EORTC-QLQ), QLQ-C30 (30 items Core Quality of Life Questionnaire, version 3.0) and with the specific module for gastric cancer QLQ-STO22 (22 items Stomach Quality of Life Questionnaire). The permission for its use by the EORTC is available.
- The EORTC-QLQ-C30 is a questionnaire that reflects the multidimensionality of HRQoL in patients with cancer. It is composed of 30 questions distributed in five functional scales (physical, role, cognitive, emotional and social), three scales of symptoms (fatigue, pain and nausea and vomiting), a global health scale and a series of additional questions to evaluate symptoms commonly referred by patients diagnosed with cancer (dyspnea, loss of appetite, insomnia, constipation and diarrhea) and the perceived financial impact.
- The EORTC-QLQ-STO22 questionnaire contains 22 structured items in five domains (dysphagia, food restrictions, pain, reflux and anxiety) and four specific items (dry mouth, alteration of taste perception, body image and hair loss) related to the symptoms of the disease.
The calculation of the sample size is based on the primary objective of comparing fragile versus non-fragile patients with respect to postoperative mortality at 90 days after the intervention. Based on mortality data previously published in a retrospective study by Mosquera et al., it is estimated that mortality for the group of non-frail patients is 0.6% and for the group with frailty 4.3%. From the data of the literature, a prevalence of 23% of frailty is calculated in the population of patients with gastric cancer and age ≥ 70 years undergoing gastrectomy.
For a power of 80% and a level of significance of 95% in a unilateral analysis, it is estimated that 276 non-fragile patients and 92 fragile patients would be needed to detect as statistically significant the difference between the proportion of patients who die between both groups.
The characteristics of fragile and non-fragile patient groups will be compared through frequency tables. The Chi-square test will be used to compare the differences between the categorical variables and the ANOVA test for the continuous variables. Different analyzes are proposed according to the study variables that are to be analyzed. For dichotomous type response variables (90- day mortality, 12-month mortality, incidence of serious complications, incidence of in-hospital death in patients with complications, and hospital readmission at 30 days after discharge), a multivariate logistic regression will be used to evaluate the risk (odds ratio) of these variables. For continuous response variables (ICC score) at 30 days after the intervention, and number of days of hospital stay), linear regression models will be used. For the variable categorical response of the patient after hospital discharge, an ordinal logistic regression model will be done. All regression models will be adjusted for age, sex, body mass index (BMI), type of gastrectomy, center volume, neoadjuvant treatment and degree of frailty. Regarding HRQoL analysis, the mean scores and 95% confidence intervals for the different domains of preoperative HRQoL and one year after surgery will be calculated. Changes of more than 10 points on a scale from 0 to 100 will be considered clinically relevant as previously suggested in other publications.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
Who may qualify
- Ages
- 70 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- The possibility to participate to the study will be offered to all the hospitals members of the Spanish EURECCA Esophagogastric Cancer Registry. The hospitals that will participate must sign a commitment. Every patient that fit the eligibility criteria will be part of the study.
Key inclusion criteria (1 listed)
- ≥ 70 years patients diagnosed with gastric cancer candidates for radical resection
Key exclusion criteria (3 listed)
- metastatic patients
- patients candidates for palliative treatment
- patients without a signed informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
90-day mortality
Time frame: 90 days after surgery
Mortality at 90 days after surgery
11 secondary outcomes
Severe complications
Time frame: 30 days after surgery
Complication Comprehensive Index
Time frame: 30 days after surgery
Failure to rescue
Time frame: 30 days after surgery
Hospital stay
Time frame: 30 days after surgery
Patient discharge facility
Time frame: 30 days after surgery
Readmission
Time frame: 30 days after discharge
12-month mortality
Time frame: 12 months after surgery
Health-related Quality of life before the intervention (EORTC-QLQ-C30)
Time frame: 2 weeks before surgery
Health-related Quality of life before the intervention (EORTC-QLQ-STO22)
Time frame: 2 weeks before surgery
Health-related Quality of life at 12 months (EORTC-QLQ-C30)
Time frame: 12 months after surgery
Health-related Quality of life at 12 months (EORTC-QLQ-STO22)
Time frame: 12 months after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Nov 2023.
- Background: PubMed 29230588Hamilton TD, Mahar AL, Haas B, Beyfuss K, Law CHL, Karanicolas PJ, Coburn NG, Hallet J. The impact of advanced age on short-term outcomes following gastric cancer resection: an ACS-NSQIP analysis. Gastric Cancer. 2018 Jul;21(4):710-719. doi: 10.1007/s10120-017-0786-6. Epub 2017 Dec 11.
- Background: PubMed 11304103Polanczyk CA, Marcantonio E, Goldman L, Rohde LE, Orav J, Mangione CM, Lee TH. Impact of age on perioperative complications and length of stay in patients undergoing noncardiac surgery. Ann Intern Med. 2001 Apr 17;134(8):637-43. doi: 10.7326/0003-4819-134-8-200104170-00008.
- Background: PubMed 24804971Kim SW, Han HS, Jung HW, Kim KI, Hwang DW, Kang SB, Kim CH. Multidimensional frailty score for the prediction of postoperative mortality risk. JAMA Surg. 2014 Jul;149(7):633-40. doi: 10.1001/jamasurg.2014.241.
- Background: PubMed 26523209Tegels JJ, Stoot JH. Way forward: Geriatric frailty assessment as risk predictor in gastric cancer surgery. World J Gastrointest Surg. 2015 Oct 27;7(10):223-5. doi: 10.4240/wjgs.v7.i10.223.
- Background: PubMed 22345294Partridge JS, Harari D, Dhesi JK. Frailty in the older surgical patient: a review. Age Ageing. 2012 Mar;41(2):142-7. doi: 10.1093/ageing/afr182.
- Background: PubMed 23764209Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, von Haehling S, Vandewoude MF, Walston J. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013 Jun;14(6):392-7. doi: 10.1016/j.jamda.2013.03.022.
- Background: PubMed 11253156Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56. doi: 10.1093/gerona/56.3.m146.
- Background: PubMed 17634318Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):722-7. doi: 10.1093/gerona/62.7.722.
- Background: PubMed 26791334McIsaac DI, Bryson GL, van Walraven C. Association of Frailty and 1-Year Postoperative Mortality Following Major Elective Noncardiac Surgery: A Population-Based Cohort Study. JAMA Surg. 2016 Jun 1;151(6):538-45. doi: 10.1001/jamasurg.2015.5085.
- Background: PubMed 16129869Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95. doi: 10.1503/cmaj.050051.
- Background: PubMed 23415494Velanovich V, Antoine H, Swartz A, Peters D, Rubinfeld I. Accumulating deficits model of frailty and postoperative mortality and morbidity: its application to a national database. J Surg Res. 2013 Jul;183(1):104-10. doi: 10.1016/j.jss.2013.01.021. Epub 2013 Feb 1.
- Background: PubMed 22250183Bellera CA, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, Soubeyran PL. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012 Aug;23(8):2166-2172. doi: 10.1093/annonc/mdr587. Epub 2012 Jan 16.
- Individual participant dataSharing planned: Undecided
Related trials for Gastric Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Manuel Pera principal investigator
Parc de Salut Mar
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric Cancer and Frail Elderly Syndrome, run by Parc de Salut Mar at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
90-day mortality (time frame: 90 days after surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03568110, which also lists 37 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2023.